Gerresheimer partners with RxCap to offer connected adherence solutions (FOTO)

Düsseldorf/Berlin/Ohio (ots) - Gerresheimer subsidiary Centor receives exclusive
distribution rights for pharmacies in the U.S.Adherence solutions enables
pharmacies to offer remote therapeutic monitoring Digital therapy support leads
to improved health outcomes

Gerresheimer, an innovative systems and solutions provider and global partner
for the pharma, biotech and cosmetics industries, has entered into a partnership
with the US digital health company RxCap and acquired a minority stake. Under
the terms of the agreement, Gerresheimer's subsidiary Centor will receive the
exclusive distribution rights for pharmacies in the U.S. for adherence solutions
by RxCap, consisting of connected prescription vial closure devices and
complementary cloud-based software. Centor is the U.S. market leader in
prescription vials and is uniquely positioned to enable smart adherence
solutions through existing pharmacy workflows.

"The adherence solutions from RxCap is an ideal complement to the Centor
prescription vials", says Tony Haba, Senior Vice President North America at
Gerresheimer. "Solutions for digital therapy support are a future growth market
for Gerresheimer. That is why we are increasingly offering our customers
innovative solutions consisting of connected primary packaging and digital
monitoring platforms. The partnership with RxCap is an excellent example of
this."

"Our mission is to help people stay adherent to their medications and improve
their care outcomes," says Sreeram Ramakrishnan, CEO of RxCap. "By partnering
with Centor - an innovative market leader with strong relations with pharmacies,
we will be able to grow the number of patients we serve. Moreover,
Gerresheimer's expertise in primary packaging and access to pharmacy leaders
will enable us to develop additional adherence solutions that amplify our
impact."

Minority shareholding and seat on the Board of DirectorsAs part of the
partnership, Gerresheimer has acquired a minority stake in RxCap in addition to
the exclusive distribution rights for pharmacies in the United States.
Gerresheimer will also appoint a representative to RxCap's Board of Directors.

Remote Therapeutic Monitoring Patient adherence to medication is crucial for
therapy outcome and can prevent cost-intensive hospitalizations. Digital therapy
support is becoming increasingly important in this area, not only through
body-worn sensors and apps, but also through connected primary packaging and
delivery systems and medication adherence monitoring.

Under the partnership agreement Centor will offer RxCap's suite of connected
prescription vial closure devices and complementary cloud-based software to
pharmacies to help them monitor their patients' prescription adherence. These
solutions require no additional effort from the patient and can easily be
integrated with existing enterprise workflows to manage patient needs
effectively.

Using a cellular signal, the RxCap reports to the cloud-based software platform
when the prescription vial has been opened. Pharmacy staff can easily and
quickly assess whether the medication has been taken as prescribed and remind
the patient to take the medication by text message or phone call.

This partnership will enable pharmacies to quickly launch adherence solutions
that can support patient's health journey more effectively, with minimal
additional investments in their workflow, and create new revenue streams.

RxCap now available for U.S. pharmacies The RxCap solution is now available for
U.S. pharmacies and can be ordered directly from Centor. Centor is thus
expanding its product offering in the U.S., positioning itself in the market for
remote therapeutic monitoring and also benefiting from recurring revenues while
making significant impact on patient health outcomes.

For order inquiries and questions, pharmacies can contact Centor at
mailto:[e-mail] .

Further information: http://www.rxcap.com

Further information: http://www.gerresheimer.com

Contact:

Gerresheimer AG
Jutta Lorberg
Head of Corporate Communication
T [phone]
mailto:[e-mail]


Marion Stolzenwald
Senior Manager Corporate Communication
T [phone]
mailto:[e-mail]

Additional content: http://presseportal.de/pm/9072/5768368
OTS: Gerresheimer AG
ISIN: DE000A0LD6E6

Die Gerresheimer Aktie wird zum Zeitpunkt der Veröffentlichung der Nachricht mit einem Minus von -0,70 % und einem Kurs von 99,80EUR auf Tradegate (29. April 2024, 14:35 Uhr) gehandelt.